Evidence map›Paper›PMID 29132274›Full record

ArticleThe Journal of neuropsychiatry and clinical neurosciences

Olanzapine Improved Symptoms and Olfactory Function in an Olfactory Reference Syndrome Patient.

Alefiya Dhilla Albers, Ilaria Amato, Mark W Albers

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of neuropsychiatry and clinical neurosciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. International consensus statement on allergy and rhinology: Olfaction.International forum of allergy & rhinology · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alefiya Dhilla AlbersFrom the Department of Neurology, Massachusetts General Hospital, Boston (ADA, IA, MWA); and the Department of Psychology, Endicott College, Beverly, Mass. (ADA).
Ilaria AmatoFrom the Department of Neurology, Massachusetts General Hospital, Boston (ADA, IA, MWA); and the Department of Psychology, Endicott College, Beverly, Mass. (ADA).
Mark W AlbersFrom the Department of Neurology, Massachusetts General Hospital, Boston (ADA, IA, MWA); and the Department of Psychology, Endicott College, Beverly, Mass. (ADA).

Funding

The Olfactory Neural Circuit as a systems Level Model of Neurodegenerative DiseasDP2OD006662 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI ALBERS, MARK W · 2009 to 2009
$2.7M
Regulatory Approval of the OLFACT Test BatteryR44AG051311 · NIA · OSMIC ENTERPRISES, INC. · PI HASTINGS, LLOYD · 2015 to 2017
$1.2M
Propagation of Neurodegeneration by Innate Immune Pattern Recognition Receptors In VivoR21NS094861 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ALBERS, MARK W · 2015 to 2016
$457k
NIA NIH HHS R44 AG051311NIH HHS DP2 OD006662NINDS NIH HHS R21 NS094861
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedHumansMaleNeuropsychological TestsOdorantsOlanzapineOlfaction DisordersOlanzapineOlanzapineOlfactionOlfactory Reference SyndromeParosmia

Identifiers

PMID29132274
PMCPMC7015176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.